Professor
CTSU, Nuffield Department of Population Health, University of Oxford
Consultant Vascular Surgeon
Gloucestershire Royal Hospital, UK
Oxford, United Kingdom
Presenter
SESSION 31: ADVANCES IN MEDICAL DIAGNOSIS AND TREATMENTS IN VASCULAR PATIENTS; NEW ANTI-ATHEROGENIC DRUGS AND LIPID MANAGEMENT
Presenter
SESSION 89: MORE HOT CAROTID TOPICS: UPDATES ON KEY CAROTID RCTS AND TREATMENT OF ASYMPTOMATIC CAROTID STENOSIS (ACS) AND POST-RADIATION STENOSIS
Presenter
SESSION 99: MEDICAL AND ADJUNCTIVE (DRUG AND CELL) TREATMENTS IN VASCULAR PATIENTS; A NEW CONCEPT; VASCULAR DISEASES; VASCULAR PROCEDURES TO FACILITATE OTHER SURGERIES
Presenter
SESSION 99: MEDICAL AND ADJUNCTIVE (DRUG AND CELL) TREATMENTS IN VASCULAR PATIENTS; A NEW CONCEPT; VASCULAR DISEASES; VASCULAR PROCEDURES TO FACILITATE OTHER SURGERIES
SESSION 31: ADVANCES IN MEDICAL DIAGNOSIS AND TREATMENTS IN VASCULAR PATIENTS; NEW ANTI-ATHEROGENIC DRUGS AND LIPID MANAGEMENT
The Risk Of Arteriosclerosis And Its Complications Are Increased By LDL Cholesterol (LDL-C) Levels: What Are The Best Medical Strategies To Decrease These Complications: Statins, Adjunctive LDL-C Lowering Drugs - Inclisiran, Bempedoic Acid, Ezetimibe, PCSK-9 Inhibitors, Lepodisiran, Colchicine, Olezarsen: How They Should Be Administered
7:10 AM - 7:15 AM
Presenter
SESSION 89: MORE HOT CAROTID TOPICS: UPDATES ON KEY CAROTID RCTS AND TREATMENT OF ASYMPTOMATIC CAROTID STENOSIS (ACS) AND POST-RADIATION STENOSIS
ACST-2 Final Results: This RCT Found That CEA And CAS For ACS Had Comparable Stroke/Death Rates For 10 Years And Implied That Both Invasive Treatments Were Superior To Now Obsolete BMT: Why This Conclusion Is No Longer Applicable
1:24 PM - 1:29 PM
Presenter
SESSION 99: MEDICAL AND ADJUNCTIVE (DRUG AND CELL) TREATMENTS IN VASCULAR PATIENTS; A NEW CONCEPT; VASCULAR DISEASES; VASCULAR PROCEDURES TO FACILITATE OTHER SURGERIES
Lowering LDL-C And Controlling Elevated Blood Pressure And Lipoprotein Little A [Lp(a)] Can Lower Cardiovascular Risk 80%: What To Do If Patients Can't Tolerate A Statin Dose: Ezetimibe (Zetia), A PCSK9 Inhibitor, Inclisiran, Bempedoic Acid (Nexletol), Etc.
2:48 PM - 2:53 PM
Presenter
SESSION 99: MEDICAL AND ADJUNCTIVE (DRUG AND CELL) TREATMENTS IN VASCULAR PATIENTS; A NEW CONCEPT; VASCULAR DISEASES; VASCULAR PROCEDURES TO FACILITATE OTHER SURGERIES
Why A New Oral PCSK9 Inhibitor (AZD0780) Will Be A Game Changer In Lipid Management And Lowering The Morbidity Of Atherosclerosis: Implications Of Its Different Mode Of Action
3:06 PM - 3:11 PM